Status:
COMPLETED
10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
50+ years
Brief Summary
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
Eligibility Criteria
Inclusion
- Early Breast Cancer patients
- Postmenopausal Status
- patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months
Exclusion
- Advanced Breast Cancer patients(stage iii, iv)
- Patients who are hard to be analysed by limitation of chart record according to investigators discretion
- patients who already have been registered in this study
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
1114 Patients enrolled
Trial Details
Trial ID
NCT00885612
Start Date
May 1 2009
End Date
March 1 2010
Last Update
June 29 2010
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cheonan, Chungcheongnam-do, South Korea
2
Research Site
Chuncheon, Gangwon-do, South Korea
3
Research Site
Goyang-si, Gyeonggi-do, South Korea
4
Research Site
Seongnam-si, Gyeonggi-do, South Korea